The Triterpenoid CDDO-Imidazolide Confers Potent Protection against Hyperoxic Acute Lung Injury in Mice
AUTOR(ES)
Reddy, Narsa M.
FONTE
American Thoracic Society
RESUMO
Rationale: Oxygen supplementation (e.g., hyperoxia) is used to support critically ill patients with noninfectious and infectious acute lung injury (ALI); however, hyperoxia exposure can potentially further contribute to and/or perpetuate preexisting ALI. Thus, developing novel therapeutic agents to minimize the side effects of hyperoxia is essential to improve the health of patients with severe ALI and respiratory dysfunction. We have previously shown that mice with a genetic disruption of the Nrf2 transcription factor, which squelches cellular stress by up-regulating the induction of several antioxidant enzymes and proteins, have greater susceptibility to hyperoxic lung injury. Moreover, we have recently demonstrated that Nrf2-deficiency impairs the resolution of lung injury and inflammation after nonlethal hyperoxia exposure.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2773914Documentos Relacionados
- Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury.
- Reciprocal backcross mice confirm major loci linked to hyperoxic acute lung injury survival time
- The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease
- IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury
- Proinflammatory role of inducible nitric oxide synthase in acute hyperoxic lung injury
